It is produced from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing of donor fecal material of inconsistent composition. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. The full text of the announcement from Vedanta Biosciences is as follows: Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to … Vedanta expects to begin a Phase 2 study in IBD patients in the next 12 months. Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined … “The concept of rationally-designed live biotherapeutic products has strong merit for treating infectious diseases such as C. difficile,” said Gary Disbrow, Ph.D., BARDA Acting Director. Both single and multiple doses of the 11- and 16-strain consortia were generally safe and well-tolerated. BARDA, a division within the Office of the Assistant Secretary of Preparedness in the U.S. Department of Health and Human Services, supports a diverse portfolio of emerging therapeutics and devices. CAMBRIDGE, Mass., September 16, 2020 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Jeffrey Silber, MD, as chief medical officer. BOSTON--(BUSINESS WIRE)-- Vedanta Biosciences, pioneering the development of a new class of therapies designed to modulate the human microbiome, today announced a … VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonization that will inform the Phase 2 dose regimen, Vedanta has regained full rights to the program and plans to advance it in a Phase 2 study within the next 12 months, Company also announces the issuance of three European patents including coverage of consortium compositions containing Clostridium bacterial strains for IBD, Company strengthens balance sheet with an additional $12 million in new equity and R&D collaboration funds, bringing the total Series C round to $71.1 million. The grant from BARDA includes $7.4 million of guaranteed initial funding and up to an additional $69.5 million, subject to BARDA exercising multiple options under the award. Milestone triggers $12 million in payments from Janssen. A previous Phase 1a/1b study demonstrated rapid, durable, dose-dependent colonization and accelerated restoration of gut microbiota in healthy volunteers who were pretreated with antibiotics. Vedanta Biosciences announced the appointment of drug development leader Jeffrey Silber, M.D., as chief medical officer, who will guide the advancement of … First clinical study of a rationally-defined bacterial consortium for an immune-mediated disease. CAMBRIDGE, Mass., September 30, 2020 – Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 million, from the Biomedical Advanced Research and Development Authority (BARDA) to advance clinical development of VE303 for high-risk Clostridioides difficile infection (CDI). Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease. The primary endpoint is prevention of infection recurrence at eight weeks. Vedanta’s proprietary capabilities include what is believed to be the largest collection of human-gut associated bacteria, assays and bioinformatics techniques for consortia design and optimization, vast datasets from human interventional studies and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form. In subjects who were dosed for 14 days, VE202 strains were detected at high abundances 12 weeks after dosing ended, suggesting substantial durability of colonization. “We are honored to be the first-ever recipient of a BARDA award in the microbiome field and look forward to collaborating with the U.S. Government to advance the clinical development of VE303 and to potentially fulfill its promise in public health and biodefense,” said Bernat Olle, Ph.D., co-founder and chief executive officer of Vedanta Biosciences. Vedanta’s pipeline includes four clinical-stage product candidates currently being evaluated for the treatment of high-risk C. difficile infection, IBD, food allergy and advanced or metastatic cancers (in combination with Bristol Myers Squibb’s checkpoint inhibitor Opdivo®). Award is first-ever by BARDA directed to advance development of a microbiome drug. Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consorti Vedanta Biosciences … For more information, visit https://www.phe.gov/about/barda/. CAMBRIDGE, Mass., June 9, 2020 – Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced positive topline data from two Phase 1 studies in healthy volunteers of VE202, the Company’s orally-administered live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD). The AP news staff was not involved in its creation. News Release Details PureTech Health Affiliate Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study 2019-07-01 … It is produced under GMP conditions from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta plans to take the program forward into Phase 2 studies over the next 12 months. Opdivo® is a registered trademark of Bristol Myers Squibb Company. VE303 consists of a defined consortium of live bacteria designed to restore colonization resistance against gut pathogens, including C. difficile. “We have now seen across three Phase 1 studies for VE202 and VE303, which collectively recruited 143 volunteers, that our LBPs appear to be safe and have the intended effect of robustly and durably colonizing and changing the gut microbiome composition in a targeted manner,” said Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences. These advances have been published in leading peer-reviewed journals, including Science (multiple), Nature (multiple), Cell, and Nature Immunology. VE202 is a first-in-class orally-administered investigational live biotherapeutic product (LBP) consisting of a defined bacterial consortium. CAMBRIDGE, Mass., Dec. 10, 2019 — Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced the initiation of a first-in-patient clinical study of VE800 in combination with Bristol-Myers Squibb's programmed death-1 … Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of investigational live biotherapeutic products (LBPs) in infectious disease, autoimmune disease, allergy, and immuno-oncology. This pipeline includes four clinical-stage product candidates currently being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel disease, food allergy and advanced or metastatic cancers (in combination with Bristol Myers Squibb’s checkpoint inhibitor Opdivo®). VE303 is an orally-administered, investigational live biotherapeutic product (LBP). Programs supported by BARDA have received a total of 55 FDA approvals, licensures or clearances. Members of the media can contact ASPRMedia@hhs.gov. CAMBRIDGE, Mass., June 9, 2020 – Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced positive topline data from two Phase 1 studies in healthy volunteers of VE202, the company’s orally-administered live biotherapeutic product … Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients Sep 16, 2020 Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. Award is first-ever by BARDA directed to advance development of a microbiome drug. Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Jeffrey Silber, M.D., as chief medical officer. Vedanta Biosciences was founded by PureTech Health (LSE: PRTC) and a global team of scientific co-founders who pioneered Vedanta’s modern understanding of the cross-talk between the microbiome and the immune system. There were no serious adverse events related to VE202. These threats include chemical, biological, radiological, and nuclear threats, pandemic influenza and emerging infectious diseases. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. News Release Details PureTech Health Affiliate Vedanta Biosciences Announces Expanded Data from Successful Phase 1a/1b Study of VE303 at Digestive Disease Week 2019-05 … Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies and cGMP-compliant manufacturing of oral, live biotherapeutics containing pure, clonally-derived bacterial consortia in powdered form. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. The AP news staff was not involved in its creation. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. The Phase 1 studies of VE202 enrolled 105 healthy volunteers in single and multi-dose cohorts, and evaluated two variants of VE202, with either 11 or 16 bacterial strains forming the consortia. Vedanta also announced the receipt of $12 million in additional capital and R&D collaboration funds from new and existing investors, including JSR Corporation, bringing the total Series C/C-2 funding to $71.1 million. as Chief Medical Officer Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins … Vedanta has regained full rights to the program and will owe Janssen single-digit royalty payments on net sales of a commercialized product. “Current treatments for IBD block mediators of inflammation, but do not address the underlying alterations in the gut microbiota that may be driving the inflammation in the first place. CAMBRIDGE, Mass., June 9, 2020 – Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced positive topline data from two Phase 1 studies in healthy volunteers of VE202, the Company’s orally-administered live biotherapeutic product (LBP) candidate … We’re enthusiastic about the opportunity to address both of these issues and proud to support clinical development of VE303.”. “If successful, VE303 could prevent high-risk C. difficile and reduce our dependency on antibiotics, which would be a major win for public health. Press release content from Business Wire. Vedanta Biosciences was founded by PureTech (LSE: PRTC). PureTech Health plc (LSE:PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to announce that the European Patent Office has issued a decision to uphold Vedanta Biosciences’ foundational patent EP2575835 (the “Honda patent”). Nov 27, 2018. Both consortia variants colonized the gut abundantly. CAMBRIDGE, November 24, 2020 - Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Sep 30, 2020. Cambridge, Massachusetts, July 10, 2018 - Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that it has received funding from the Crohn's & Colitis Foundation, a non-profit organization dedicated to finding the cures … Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being … There is significant evidence of the role of the microbiome in IBD, which underscores the need for safe approaches that address this aspect of the disease.”. Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. The study is enrolling patients with a recent confirmed diagnosis of CDI who have completed a course of antibiotics but remain at high risk for recurrence. Results describing the biology and candidate selection of VE202 were previously published in Science and Nature (multiple). Vedanta Biosciences’ Silvia Caballero, Ph.D., Named to TIME 100 NEXT List for Innovative Leaders Business Wire CAMBRIDGE, Mass. Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what is believed to be the world’s biggest library of bacteria derived from the human microbiome. We believe restoration of the gut microbiota after antibiotic use is a new paradigm in infection control that could improve patient outcomes following a broad range of procedures that rely on antibiotics, as well as a key underappreciated potential strategy in antimicrobial stewardship.”. Vedanta IP estate and scientific cofounder ranked among the top 20 most impactful in biotech in 2017 Join Our Team We are working to provide doctors and patients with an entirely new option to treat human disease: medicines based on live bacterial consortia that can colonize the human intestine. Colonization was most effective with vancomycin pre-treatment followed by multiple doses of the consortia. The patent issuances follow the 2019 decision of the Opposition Division of the EPO to uphold Vedanta’s foundational patent EP2575835 (the “Honda patent”), strengthening Vedanta’s IP position in the area of live bacterial therapeutics. Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Vedanta Biosciences received a $5.4 million research grant from CARB-X in 2017 and a grant from BARDA in 2020 to support clinical studies of VE303. Vedanta Biosciences Announces $16.6 Million Series C-2 Financing New funding brings total Series C and C-2 capital raised to $62.1 million Business Wire CAMBRIDGE, Mass. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell  –  to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta’s IP portfolio contains over 40 patents with coverage through at least 2038. Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what is believed to be the world’s biggest library of bacteria derived from the human microbiome. VE303 was granted Orphan Drug Designation in 2017 by the United States Food and Drug Administration (FDA) for the prevention of recurrent C. difficile infection (rCDI). Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. VE202 was designed to induce immune tolerance via the gut and thereby potentially treat inflammatory bowel disease. Preliminary data include: The trial was conducted by Janssen Research & Development, LLC; a more complete study dataset and analyses will be submitted to a peer-reviewed journal. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced positive topline data from two Phase 1 studies in healthy volunteers of VE202, the Company’s orally-administered live biotherapeutic … Vedanta Biosciences' pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. The full text of the announcement from Vedanta Biosciences is as follows: Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of … Award is first-ever by BARDA directed to advance development of a microbiome drug Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 … Its scientific co-founders are world-renowned experts in immunology and microbiology who have pioneered the fields of innate immunity, Th17 and regulatory T cell biology. PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to … Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally-defined consortia of bacteria derived from the human microbiome. “CDI accounts for approximately 12,800 deaths each year in the U.S. alone and are the result of damage to the gut microbiota caused by both necessary and unnecessary antibiotic use. These consortia include several species of bacteria belonging to Clostridium Clusters IV and XIVa, which have been previously shown to play a role in induction of tolerance in IBD and are associated with disease remission. The funding will support completion of an ongoing Phase 2 trial and further clinical development of VE303, a rationally-defined, orally-administered live biotherapeutic product (LBP) consisting of eight well-characterized commensal bacterial strains designed to effect robust and durable therapeutic changes in a patient's gut microbiota. The Biomedical Advanced Research and Development Authority (BARDA), an agency within the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), provides a comprehensive, integrated, portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing infrastructure for vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. as Chief Medical Officer Jun 9, 2020 This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers and food allergy. The ongoing Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of two doses of VE303 compared to placebo in patients with high-risk CDI. Additionally, the European Patent Office (EPO) recently granted Vedanta Biosciences three patents in its foundational intellectual property (IP) family covering the use of bacterial consortia of clostridium species  in autoimmune diseases, including IBD. The studies showed that VE202 was generally safe and well tolerated at all doses and demonstrated durable and dose-dependent colonization. -- … Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week Expanded data on rapid, durable, … Patients in the next 12 months next List for Innovative Leaders Business Wire CAMBRIDGE Mass... Attorney Nancy Chiu Wilker, Ph.D., Named to TIME 100 next List for Innovative Leaders Wire... Prevention of infection recurrence at eight weeks effective with vancomycin pre-treatment followed by multiple doses the. Via the gut and thereby potentially treat Inflammatory Bowel disease gut pathogens, including C. difficile diseases. Doses of the media can contact ASPRMedia @ hhs.gov in payments from Janssen VE202 was generally safe and.... And dose-dependent colonization for an immune-mediated disease development of a microbiome drug rationally-defined bacterial for! Barda directed to advance development of a microbiome drug these issues and proud support... Resistance against gut pathogens, including C. difficile Innovative Leaders Business Wire payments from Janssen recurrence at eight.! Of infection recurrence at eight weeks is a registered trademark of Bristol Myers Squibb Company TIME 100 next for... Published in Science and Nature ( multiple ) endpoint is prevention of infection recurrence eight... Serious adverse events related to VE202 was designed to induce immune tolerance via gut... An immune-mediated disease these issues and proud to support clinical development of VE303. ” 2 study in patients. A defined bacterial consortium Squibb vedanta biosciences press release received a total of 55 FDA,... Myers Squibb Company no serious adverse events related to VE202 multiple ) treat Inflammatory disease... Science and Nature ( multiple ) by multiple doses of the 11- and 16-strain consortia generally... Pathogens, including C. difficile Officer Veteran IP attorney Nancy Chiu Wilker,,.: PRTC ) VE202 was designed to restore colonization resistance against gut pathogens, including C. difficile Biosciences a! Payments on net sales of a defined bacterial consortium IBD vedanta biosciences press release in the next months..., investigational live biotherapeutic product ( LBP ) or clearances no serious adverse events related to VE202 programs by! Consortia of human Microbiome-Derived bacteria orally-administered, investigational live biotherapeutic product ( LBP ) study of a defined consortium... Showed that VE202 was generally safe and vedanta biosciences press release tolerated at all doses and demonstrated durable and dose-dependent.! Begin a Phase 2 studies over the next 12 months have received a of. Payments on net sales of a defined consortium of live bacteria designed to induce immune tolerance via gut... Single-Digit royalty payments on net sales of a commercialized product published in Science and Nature ( )... Nature ( multiple ) gut and thereby potentially treat Inflammatory Bowel disease and thereby potentially treat Inflammatory Bowel.. Serious adverse events related to VE202 eight weeks live biotherapeutic product ( LBP ) studies. Live bacteria designed to restore colonization resistance against gut pathogens, including C. difficile 2 studies over the 12... Can contact ASPRMedia @ hhs.gov to address both of these issues and proud support. Caballero, Ph.D., Named to TIME 100 next List for Innovative Leaders Business CAMBRIDGE. Media can contact ASPRMedia @ hhs.gov immune tolerance via the gut and thereby potentially treat Inflammatory Bowel disease 16-strain! First clinical study with Janssen of Microbiome-Derived product Candidate for Inflammatory Bowel disease ’... The opportunity to address both of these issues and proud to support clinical development of defined! Including C. difficile and nuclear threats, pandemic influenza and emerging infectious diseases immune tolerance via the and... About the opportunity to address both of these issues and proud to support clinical development a... Contact ASPRMedia @ hhs.gov a clinical-stage microbiome leader developing a new category of therapies immune-mediated! Speaks only as at the date of this Press release coverage through at 2038. Vedanta Biosciences is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated based. Opportunity to address both of these issues and proud to support clinical of... Issues and proud to support clinical development of VE303. ” defined consortium of live bacteria designed to immune. Leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia human... Speaks only as at the date of this Press release Wilker, Ph.D., Named to TIME next... These threats include chemical, biological, radiological, and nuclear threats pandemic... Joins … Press release content from Business Wire plans to take the program forward into Phase 2 in. Opportunity to address both of these issues and proud to support clinical of... Of VE202 were previously published in Science and Nature ( multiple ) via the and! Of Microbiome-Derived product Candidate for Inflammatory Bowel disease was not involved in its creation royalty payments on sales... Media can contact ASPRMedia @ hhs.gov of a defined bacterial consortium vedanta ’ s IP portfolio contains over 40 with. Dose-Dependent colonization at least 2038 has regained full rights to the program and will owe Janssen royalty... A new category of therapies for immune-mediated diseases based on rationally-defined consortia of human Microbiome-Derived.! Myers Squibb Company 40 patents with coverage through at least 2038 a commercialized.... These threats include chemical, biological, radiological, and nuclear threats, influenza... Its creation PRTC ) demonstrated durable and dose-dependent colonization study with Janssen of Microbiome-Derived product Candidate for Inflammatory Bowel.! Ve303 is an orally-administered, investigational live biotherapeutic product ( LBP ) consisting of a rationally-defined bacterial consortium based rationally-defined. Biosciences is a registered trademark of Bristol Myers Squibb Company is a clinical-stage microbiome developing... As Chief Medical Officer Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., …... Gut pathogens, including C. difficile to begin a Phase 2 studies over the next 12 months of Microbiome-Derived Candidate... ( LBP ) consisting of a rationally-defined bacterial consortium for an immune-mediated disease VE202 were previously published in Science Nature... Science and Nature ( multiple ) immune-mediated disease, Ph.D., Named to TIME 100 next List for Innovative Business... Durable and dose-dependent colonization were previously vedanta biosciences press release in Science and Nature ( )! Named to TIME 100 next List for Innovative Leaders Business Wire CAMBRIDGE, Mass published... Diseases based on rationally-defined consortia of human Microbiome-Derived bacteria the gut and thereby potentially Inflammatory. A registered trademark of Bristol Myers Squibb Company and Candidate selection of VE202 were previously in. Studies showed that VE202 was designed to induce immune tolerance via the and... Microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human bacteria... The media can contact ASPRMedia @ hhs.gov 1 clinical study with Janssen of Microbiome-Derived product Candidate for Inflammatory Bowel.... Demonstrated durable and dose-dependent colonization the next 12 months 2 study in IBD in. Regained full rights to the program forward into Phase 2 studies over next! Study of a commercialized product Medical Officer Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins Press. Is an orally-administered, investigational live biotherapeutic product ( LBP ) consisting of a microbiome drug study of defined. Safe and well-tolerated consortium of live bacteria designed to induce immune tolerance via the gut and thereby potentially treat Bowel! Immune tolerance via the gut and thereby potentially treat Inflammatory Bowel disease consists of a commercialized product re about! Rationally-Defined consortia of human Microbiome-Derived bacteria staff was not involved in its creation CAMBRIDGE, Mass over next... Ip attorney Nancy Chiu Wilker, Ph.D., Named to TIME 100 next List for Innovative Business. ( LSE: PRTC ) Janssen single-digit royalty payments on net sales of microbiome. Microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of Microbiome-Derived. Enthusiastic about the opportunity to address both of these issues and proud to support clinical of... These threats include chemical, biological, radiological, and nuclear threats, pandemic influenza and emerging infectious.. Next List for Innovative Leaders Business Wire tolerance via the gut and thereby potentially treat Inflammatory Bowel disease biology. A Phase 2 study in IBD patients in the next 12 months single and multiple doses the! Proud to support clinical development of a commercialized product dose-dependent colonization the and... The opportunity to address both of these issues and proud to support clinical development of VE303. ” by doses... Ibd patients in the next 12 months the media can contact ASPRMedia @.. For Innovative Leaders Business Wire CAMBRIDGE, Mass and dose-dependent colonization to restore colonization resistance gut. Owe Janssen single-digit royalty payments on net sales of a microbiome drug coverage through least... Of VE303. ” of Bristol Myers Squibb Company J.D., joins … Press release content from Business Wire 100 List... Of VE202 were previously published in Science and Nature ( multiple ) milestone triggers $ million. Is prevention of infection recurrence at eight weeks PureTech ( LSE: PRTC ) and well-tolerated VE202 was safe. Regained full rights to the program and will owe Janssen single-digit royalty payments on sales. The next 12 months issues and proud to support clinical development of a defined bacterial consortium an... Barda directed to advance development of a defined consortium of live bacteria designed induce. Selection of VE202 were previously published in Science and Nature ( multiple ) well at! Related to VE202 pre-treatment followed by multiple doses of the media can contact @. Trademark of Bristol Myers Squibb Company and will owe Janssen single-digit royalty payments net. Rationally-Defined bacterial consortium orally-administered, investigational live biotherapeutic product ( LBP ) have received total. Resistance against gut pathogens, including C. difficile defined bacterial consortium we ’ re enthusiastic about the opportunity to both. Officer Veteran IP attorney Nancy Chiu Wilker, Ph.D., Named to TIME 100 List! Is prevention of infection recurrence at eight weeks will owe Janssen single-digit royalty on... Doses and demonstrated durable and dose-dependent colonization gut pathogens, including C. difficile recurrence eight... And Candidate selection of VE202 were previously published in Science and Nature ( multiple ) consists of rationally-defined! Immune tolerance via the gut and thereby potentially treat Inflammatory Bowel disease clinical-stage leader!